The Committee discusses Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) 125387, Aflibercept Solution for intravitreal injection in a virtual meeting to be held on January 9 at 9:30 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- FDA Dermatologic & Ophthalmic Drugs Advisory Committee Virtual Meeting
- 2seventy Bio announces amendment to collaboration with Regeneron
- CytomX Therapeutics updates business, announces 2023 relationship with Moderna
- Sensei announces clinical supply agreement with Regeneron for Libtayo
- Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023